<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zymeworks Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock</link>
<description>Latest news and press releases for Zymeworks Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zymeworks-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ddc578dffbe2df124de6.webp</url>
<title>Zymeworks Inc. Common Stock</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock</link>
</image>
<item>
<title>Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-to-report-first-quarter-2026-financial-results-and-host-conference-call-on-may-7-2026</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed</description>
</item>
<item>
<title>Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-additional-leadership-appointments-to-advance-next-phase-of-growth</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>• Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE</description>
</item>
<item>
<title>Zymeworks Appoints Kristin Stafford as Chief Financial Officer</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-appoints-kristin-stafford-as-chief-financial-officer-7</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-appoints-kristin-stafford-as-chief-financial-officer-7</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed</description>
</item>
<item>
<title>Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-receives-us-fda-fast-track-designation-for-zw191-an-fra-targeting-antibody-drug-conjugate</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-receives-us-fda-fast-track-designation-for-zw191-an-fra-targeting-antibody-drug-conjugate</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or</description>
</item>
<item>
<title>Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-presentations-for-ziiherar-zanidatamab-hrii-at-2026-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-presentations-for-ziiherar-zanidatamab-hrii-at-2026-aacr-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology VANCOUVER, British Columbia, March 18, 2026 (GLOBE</description>
</item>
<item>
<title>Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-to-present-clinical-and-preclinical-data-on-adc-programs-including-novel-ras-adc-platform-at-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-to-present-clinical-and-preclinical-data-on-adc-programs-including-novel-ras-adc-platform-at-aacr-annual-meeting</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21Preclinical data highlight combination potential for ZW191, a</description>
</item>
<item>
<title>Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/royalty-pharma-and-zymeworks-enter-into-dollar250-million-royalty-backed-note-financing</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/royalty-pharma-and-zymeworks-enter-into-dollar250-million-royalty-backed-note-financing</guid>
<pubDate>Mon, 02 Mar 2026 11:10:00 GMT</pubDate>
<description>Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisition</description>
</item>
<item>
<title>Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-and-royalty-pharma-enter-into-dollar250-million-royalty-backed-note-financing</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-and-royalty-pharma-enter-into-dollar250-million-royalty-backed-note-financing</guid>
<pubDate>Mon, 02 Mar 2026 11:01:00 GMT</pubDate>
<description>Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisition</description>
</item>
<item>
<title>Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive (HER2+)</description>
</item>
<item>
<title>Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-report-fourth-quarter-full-110000830</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-report-fourth-quarter-full-110000830</guid>
<pubDate>Thu, 12 Feb 2026 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a</description>
</item>
<item>
<title>Zymeworks Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-participation-upcoming-investor-110000304</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-participation-upcoming-investor-110000304</guid>
<pubDate>Tue, 27 Jan 2026 11:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Citi’s 2026 Virtual Oncology Leadership Summit: Zymeworks’ management will participate in one-on-one meetings February 18-19, 2026 virtually.TD Cowen 46th</description>
</item>
<item>
<title>Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-leadership-appointments-transitions-110000887</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-leadership-appointments-transitions-110000887</guid>
<pubDate>Mon, 12 Jan 2026 11:00:00 GMT</pubDate>
<description>Investment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating OfficerFive new Vice Presidents appointed, underscoring our commitment to leadership development VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets</description>
</item>
<item>
<title>Zymeworks Outlines Strategic Priorities and Outlook for 2026</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-outlines-strategic-priorities-outlook-230000955</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-outlines-strategic-priorities-outlook-230000955</guid>
<pubDate>Sun, 11 Jan 2026 23:00:00 GMT</pubDate>
<description>Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and ChinaCompany well-positioned to execute new strategy compounding long-term value by integrating royalty growth, strategic acquisitions, and continued internal R&D innovation$125</description>
</item>
<item>
<title>Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-in-first-line-her2-locally-advanced-or-metastatic-gea-including-more-than-two-years-median-overall-survival-benefit</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/ziiherar-zanidatamab-hrii-combinations-achieve-unprecedented-results-in-first-line-her2-locally-advanced-or-metastatic-gea-including-more-than-two-years-median-overall-survival-benefit</guid>
<pubDate>Tue, 06 Jan 2026 18:34:00 GMT</pubDate>
<description>Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 statusLate-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026Ziihera engineered and initially developed by Zymeworks using our proprietary Azymetric™ technology plat</description>
</item>
<item>
<title>Zymeworks Announces Participation in Upcoming Conferences</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-participation-upcoming-conferences-210500691</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-participation-upcoming-conferences-210500691</guid>
<pubDate>Tue, 02 Dec 2025 21:05:00 GMT</pubDate>
<description>• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI • Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasd</description>
</item>
<item>
<title>Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-appoints-scott-platshon-acting-060100036</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-appoints-scott-platshon-acting-060100036</guid>
<pubDate>Tue, 18 Nov 2025 06:01:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer. Mr. Platshon will report directly to Zymeworks’ Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows f</description>
</item>
<item>
<title>Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-strategic-initiative-optimize-060000929</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-strategic-initiative-optimize-060000929</guid>
<pubDate>Tue, 18 Nov 2025 06:00:00 GMT</pubDate>
<description>Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholdersStrategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J)Eligible to receive up to $440.0 million in potential near-term milestone payments upon successful global regulator</description>
</item>
<item>
<title>Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-positive-herizon-gea-110000932</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-announces-positive-herizon-gea-110000932</guid>
<pubDate>Mon, 17 Nov 2025 11:00:00 GMT</pubDate>
<description>Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysisZiihera plus Tevimbra® (tislelizumab) and chemotherapy demonstrated clinically meaningful and statistically significant improvements in OS and PFS versus trastuzumab and chemotherapyResults support Ziihera’s potential to be the HE</description>
</item>
<item>
<title>Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-provides-corporate-reports-third-210500682</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-provides-corporate-reports-third-210500682</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC ConferenceFirst patient dosed in Phase 1 clinical trial of ZW251 for the treatment of hepatocellular carcinomaAchievement of $25.0 million development milestone from Johnson & Johnson Innovative MedicineEarned royalties of $1.0 million based on Ziihera® net product sales by Jazz and BeOne Medicines for 3Q-2025Completed share repurchases of $22.7 million under sha</description>
</item>
<item>
<title>Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference</title>
<link>https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-presents-initial-clinical-data-163000098</link>
<guid isPermaLink="true">https://6ix.com/company/zymeworks-inc-common-stock/news/zymeworks-presents-initial-clinical-data-163000098</guid>
<pubDate>Thu, 23 Oct 2025 16:30:00 GMT</pubDate>
<description>Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall response rate in gynecological cancers at doses ≥6.4mg/kgResponses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks’ novel antibody-drug conjugate platformDose optimization of ZW191 in ovarian cancer to initiate in 4Q-2025Investo</description>
</item>
</channel>
</rss>